March 1, 2019
- Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25 mg, 50 mg and 100 mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient (API)
- Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry (PDF - 323KB)
- FDA Drug Shortages
- Cefazolin Injection (Updated - Currently in Shortage)
- Cefepime Injection (Updated - Currently in Shortage)
- Cefepime Injection (Updated - Discontinuation)
- Ondansetron Hydrochloride Injection (Updated - Currently in Shortage)
- Piperacillin and Tazobactam (Zosyn) Injection (Updated - Currently in Shortage)
- La FDA agrega un Recuadro de advertencia por el aumento en el riesgo de muerte con el medicamento para la gota Uloric (febuxostat)
.png)
No hay comentarios:
Publicar un comentario